Platform Technology
The foundation of TRT's Mesenchymal Stromal/Stem Cell (MSC) platform technology is the extensive intellectual property we have developed for the production of the TXP family of therapeutic products. The TXP product family is based on the extraction and isolation of MSCs from a completely non-controversial source of neo-natal human tissue - the umbilical cord. The extracted cells are known as Human Umbilical Cord PeriVascular Cells (HUCPVC). The core of the HUCPVC intellectual property is the extensive patent estate of four patent families represented by over eighty patents and patent applications worldwide. This platform technology represents the world's richest source of MSCs.

- Produced in entirely serum-free conditions - unlike other MSC sources. This removes the risk of contamination by animal products.
- Easily obtainable and a rich source of MSCs. Their frequency at harvest is 1:300 as opposed to the much lower yield of 1:100,000 from bone marrow.
- TXP cells are more biologically (physiologically) potent e.g. higher expression of wound healing genes than MSCs sourced from adult tissues (marrow or fat).
- Proven efficacy in wound healing of several tissues: bone, cartilage, skin etc.
- TXP cells are immunosuppressive and non-alloreactive - characters that have been confirmed by leading international clinician scientists